In patients with TBI, intravenous cerebrolysin significantly increased Glasgow Outcome Scale scores versus placebo.
In plain wordsIn patients with brain injury, cerebrolysin improved Glasgow Outcome Scale scores compared with placebo.
- Peptide
- Cerebrolysin
- Outcome
- IncreaseGlasgow Outcome Scale score
- Study
n: not reported in source
- Comparator
- Placebo
- Outcome group
- Exercise and physical function · Nervous system and cognition
- Studied dose
- Dose not stated · intravenousAs given in this study (human).
Measurements
- SMD
- 0.3
- Glasgow Outcome Scale
- 95% CI
- 0.18 to 0.42
- Glasgow Outcome Scale
- P value for pooled Glasgow Outcome Scale score
- < 0.001
- Intravenous cerebrolysin versus placebo, random-effects meta-analysis
- I-squared heterogeneity for pooled Glasgow Outcome Scale estimate
- 87.8%
- Random-effects meta-analysis of Glasgow Outcome Scale score
Source sentences
The overall pooled findings using random-effects models among patients with TBI indicated that intravenous administration of cerebrolysin significantly increased Glasgow Outcome Scale score (SMD =0.30; 95% CI: 0.18 to 0.42; PI 2: 87.8%)
2 context sentences(design, population, supporting numbers)
All the relevant studies with randomized clinical trial and cohort design evaluating the effects of intravenous cerebrolysin vs placebo on functional outcome of patients with TBI within the English literature up to October 2018 were included.
Five articles (5,685 participants) were included in the current meta-analysis.